Arrowhead Pharmaceuticals’ (ARWR) “Neutral” Rating Reiterated at Chardan Capital

Chardan Capital reissued their neutral rating on shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in a report issued on Wednesday.

A number of other brokerages also recently commented on ARWR. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, September 1st. Cantor Fitzgerald reaffirmed a hold rating and set a $2.00 target price (up from $1.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday. Piper Jaffray Companies reiterated a hold rating and set a $2.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, July 28th. Finally, Jefferies Group LLC reiterated a hold rating and set a $2.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, August 4th. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the stock. Arrowhead Pharmaceuticals presently has an average rating of Hold and a consensus price target of $2.00.

Shares of Arrowhead Pharmaceuticals (ARWR) traded up 18.28% during trading on Wednesday, reaching $3.30. 3,647,096 shares of the company traded hands. Arrowhead Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $8.09. The stock’s market capitalization is $246.75 million. The firm has a 50 day moving average of $2.41 and a 200 day moving average of $1.88.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. The company had revenue of $9.34 million for the quarter, compared to the consensus estimate of $5.29 million. On average, equities analysts predict that Arrowhead Pharmaceuticals will post ($0.42) EPS for the current year.

WARNING: “Arrowhead Pharmaceuticals’ (ARWR) “Neutral” Rating Reiterated at Chardan Capital” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/09/16/arrowhead-pharmaceuticals-arwr-neutral-rating-reiterated-at-chardan-capital.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. Teachers Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 18.0% during the fourth quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company’s stock valued at $175,000 after acquiring an additional 17,201 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Arrowhead Pharmaceuticals by 3.7% during the first quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock valued at $581,000 after acquiring an additional 11,099 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Arrowhead Pharmaceuticals by 144.8% during the first quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock valued at $278,000 after acquiring an additional 88,933 shares during the last quarter. LMR Partners LLP acquired a new stake in shares of Arrowhead Pharmaceuticals during the second quarter valued at about $467,000. Finally, SG Americas Securities LLC increased its position in shares of Arrowhead Pharmaceuticals by 287.9% during the first quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 74,776 shares during the last quarter. Institutional investors and hedge funds own 20.63% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply